Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyThoracic TumorsDiseaseEsophageal CancerSubgroupICD10C15.-MeSHEsophageal NeoplasmsSequenceSERP4,5/NPAC260/CRBP5, Esophageal Cancer, neoadjuvant (PID3210) -|- SERP4,5, Esophageal Cancer, adjuvant (PID3227)ChemotherapyChemo-substanceCarboplatinNab-paclitaxelSerplulimabChemo-substanceCarboplatinNab-paclitaxelSerplulimabChemo-substanceCarboplatinNab-paclitaxelSerplulimabChemo-substanceCarboplatinNab-paclitaxelSerplulimabNo. Substances13 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNo. Substances14Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseneoadjuvantTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Pneumonitis only studiesPublicationAuthorWu ZDiseaseÖsophaguskarzinom, resezierbar, Stadium II-IVA, ECOG 0-1OriginDepartment of Thoracic Surgery, Zhejiang University School of Medicine, Hangzhou, ChinaProtocols in Revision 2 protocols foundSerplulimab 4.5 / Nab-palitaxel 260 / Carboplatin 5 - Serplulimab 4.5, Esophageal Cancer, adjuvant (PID3227 V1.0)Serplulimab 4.5 / Nab-palitaxel 260 / Carboplatin 5, Esophageal Cancer, neoadjuvant (PID3210 V1.0)
